Skip to main content
Figure 1 | Radiation Oncology

Figure 1

From: Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer

Figure 1

Expression of RTK’s detected by western blot analysis. Three prostate cell lines PC3, LNCaPs and DU145 were assessed for the presence of RTKs, shown to be targets of sunitinib (c-KIT, VEGFR-2, PDGFR- and FLT3). DU145 was found to be positive for all except for FLT3. PDGFR- was the only RTK found to be expressed in PC3 cells while LNCaPs were found to be negative for all four.

Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us